← board
NPHC
distress 4/10 · elevated risk$0.000%today-70% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+1%
Price & events
+50.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+50.0%
1M
+0.0%
3M
+50.0%
6M
+50.0%
1Y
+200.0%
2Y
-95.6%
5Y
-72.7%
All
Overview
- Market Cap
- $2.15M
- Enterprise Value
- $2.27M
- Volume
- 0
- 52 Week Range
- $0.00 – $0.00
- Total Shares
- 7.16B
- Float Shares
- 7.09B
- % Held by Insiders
- 1.02%
- % Held by Institutions
- 0.00%
- Beta
- 58.55
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 7,159,727,214 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.